Bristol-Myers Squibb Company (BMY)
BMY · Health Care · 
United States
Bristol-Myers Squibb Company (BMY) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 1.87%. Anyone who holds an ETF containing Bristol-Myers Squibb Company also has an indirect stake in the company.
Data and Charts: Bristol-Myers Squibb Company
Key Data for Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Stock Price Chart
The Bristol-Myers Squibb Company chart shows daily closing prices and is set to the current year by default. The stock is up 15.8% year to date and up 37.0% over twelve months. The last recorded close on October 30, 2026, was $62.48, at 75% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
Bristol-Myers Squibb Company Stock Performance
| Year to date | +15.8% | 1 year | +37.0% |
|---|---|---|---|
| 1 month | +0.1% | 3 months | -4.3% |
| Calendar year 2025 | -4.6% |
Measured in euros, Bristol-Myers Squibb Company is up 21.8% year to date and up 41.6% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Connections
The map shows how Bristol-Myers Squibb Company connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- United States Country · domicile
- XUHL ETF · holds
- ZPRG ETF · holds
- XUHC ETF · holds
- XDWH ETF · holds
- ZPD3 ETF · holds
- SPFS ETF · holds
- Health Care Sector · sector
- Centene Corporation Stock · similar ETF exposure
What ETF Is Bristol-Myers Squibb Company In?
Bristol-Myers Squibb Company has very high ETF coverage and is held by 26 of the 104 ETFs we track, which together follow 13 indices. That puts the stock in more ETFs than 94.3% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 1.87% | €18.68 |
| SPFS | MSCI World Health Care | 1.38% | €13.84 |
| XDWH | MSCI World Health Care | 1.38% | €13.82 |
| ZPD3 | S&P Global Dividend Aristocrats | 1.35% | €13.50 |
| ZPRG | S&P Global Dividend Aristocrats | 1.25% | €12.49 |
| XDEV | MSCI World Value | 0.65% | €6.46 |
| XDEM | MSCI World Momentum | 0.37% | €3.71 |
| WVAL | MSCI World Value | 0.36% | €3.62 |
| XDEQ | MSCI World Quality | 0.24% | €2.36 |
| SXR8 | S&P 500 | 0.19% | €1.90 |
| SPYL / SPY5 | S&P 500 | 0.19% | €1.89 |
| XD9U / XD9D | MSCI USA | 0.19% | €1.88 |
| XDEW | S&P 500 Equal Weight | 0.18% | €1.85 |
| SWWD | MSCI World | 0.14% | €1.41 |
| SPPW | MSCI World | 0.14% | €1.41 |
| EUNL | MSCI World | 0.14% | €1.40 |
| XDWD / XDWL | MSCI World | 0.14% | €1.37 |
| SPYI / SPSA | MSCI ACWI IMI | 0.13% | €1.33 |
| SPYY | MSCI ACWI | 0.12% | €1.23 |
| WIMI | MSCI World IMI | 0.12% | €1.23 |
| IUSQ | MSCI ACWI | 0.12% | €1.20 |
The last column shows how much of €1,000 in one of these funds goes to Bristol-Myers Squibb Company, based on each fund's latest holdings list.
US-listed ETFs holding Bristol-Myers Squibb Company (weight per latest SEC filing): SCHD 3.32%, VYM 0.54%, IVV 0.18%, SPY 0.18%, VOO 0.18%, VTI 0.16%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Bristol-Myers Squibb Company Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Bristol-Myers Squibb Company had a weight of 0.20% on Sep 30, 2019 and 0.14% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.37% on Mar 31, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Bristol-Myers Squibb Company overlaps with the rest of a portfolio.
Stocks With ETF Exposure Similar to Bristol-Myers Squibb Company
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | – | – | +37.0% | 28.4% | 14.6% | -0.2% |
 Pfizer | 24 | +0.66 | +25.6% | 23.9% | 12.4% | -1.6% |
 CVS Health Corporation | 23 | – | +17.7% | 33.6% | 0.4% | +7.8% |
 Biogen | 23 | +0.63 | +69.5% | 32.1% | 13.1% | +2.2% |
| Centene Corporation | 23 | – | +95.5% | 50.4% | -3.4% | +19.4% |
| Cooper Companies | 22 | – | -15.1% | 33.3% | 9.2% | +5.1% |
 Zimmer Biomet Holdings | 22 | – | -5.1% | 29.5% | 8.6% | +7.2% |
 Illumina | 21 | – | +138.3% | 47.5% | 19.6% | -0.7% |
 ResMed | 21 | – | -8.8% | 28.8% | 26.9% | +9.9% |
These stocks reach a portfolio through largely the same funds as Bristol-Myers Squibb Company. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 45.0 | 8.0 | 17.8% |
| FY ended Dec 2024 | 48.3 | -8.9 | -18.5% |
| FY ended Dec 2025 | 48.2 | 7.1 | 14.6% |
Technical Analysis: Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Risk Metrics
The close on Oct 30, 2026, was 8.2% below the highest close since Aug 12, 2024. That high was reached on Sep 3, 2026. When the S&P 500 rose or fell 1%, Bristol-Myers Squibb Company moved 0.17% on average in the same direction (past 252 trading days). The correlation of 0.08, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Bristol-Myers Squibb Company.
What Bristol-Myers Squibb Company Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Pfizer Inc. | +0.66 | |
| Biogen Inc. | +0.63 | |
| Royalty Pharma Plc Class A | +0.62 | |
| Gilead Sciences Inc. | +0.60 | |
| Eli Lilly and Company | +0.51 | |
| Amgen Inc. | +0.50 | |
| YB | -0.51 | |
| Nikkei 225 | -0.40 | |
| Monolithic Power Systems Inc. | -0.35 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
